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Abstract
Since the publication of the Duchenne muscular dystrophy (DMD) care considerations in 2010, 
multidisciplinary care of this severe, progressive neuromuscular disease has evolved. In 
conjunction with improved patient survival, a shift to more anticipatory diagnostic and therapeutic 
strategies has occurred, with a renewed focus on patient quality of life. In 2014, a steering 
committee of experts from a wide range of disciplines was established to update the 2010 DMD 
care considerations, with the goal of improving patient care. The new care considerations aim to 
address the needs of patients with prolonged survival, to provide guidance on advances in 
assessments and interventions, and to consider the implications of emerging genetic and molecular 
therapies for DMD. The committee identified 11 topics to be included in the update, eight of 
which were addressed in the original care considerations. The three new topics are primary care 
and emergency management, endocrine management, and transitions of care across the lifespan. In 
part 1 of this three-part update, we present care considerations for diagnosis of DMD and 
neuromuscular, rehabilitation, endocrine (growth, puberty, and adrenal insufficiency), and 
gastrointestinal (including nutrition and dysphagia) management.
Introduction
Duchenne muscular dystrophy (DMD) is a lethal X-linked recessive neuromuscular disorder 
caused by mutations in the dystrophin gene that result in absent or insufficient functional 
dystrophin, a cytoskeletal protein that enables the strength, stability, and functionality of 
myofibres. Prevalence of DMD has been reported as 15.9 cases per 100 000 live male births 
in the USA and 19.5 cases per 100 000 live male births in the UK.1–3 Progressive muscular 
damage and degeneration occurs in people with DMD, resulting in muscular weakness, 
associated motor delays, loss of ambulation, respiratory impairment, and cardiomyopathy. 
Although the clinical course of skeletal muscle and cardiac involvement can be variable, 
death usually occurs as a result of cardiac or respiratory compromise.4,5 This is part 1 of a 
three-part update of the 2010 DMD care considerations,6–8 which has been supported by the 
US Centers for Disease Control and Prevention (CDC) with involvement of the TREAT-
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NMD network for neuromuscular diseases, the Muscular Dystrophy Association, and Parent 
Project Muscular Dystrophy.
The decision to update the care considerations was driven by several important 
developments. First, with multidisciplinary care, the survival of patients with DMD has 
improved, and the diagnostic and therapeutic approach of the relevant subspecialties is 
evolving.9–12 With more widespread realisation of prolonged survival, multiple 
subspecialties have shifted to more anticipatory diagnostic and therapeutic strategies, to 
achieve prevention, early identification, and treatment of predictable and potentially 
modifiable disease complications. Second, accompanying the expectation of longer survival 
is an increasing emphasis on quality of life and psychosocial management. Moreover, an 
urgent need now exists to coordinate and improve patient transitions from childhood to 
adulthood. Third, this update was necessitated by the growing experience with existing 
therapies and the anticipation of emerging genetic and molecular therapies for DMD.13 
Specifically, new information is available on the efficacy, side-effects, and limitations of 
glucocorticoids,14,15 and clinically meaningful and reliable biomarkers and outcome 
measures need to be identified to assess emerging therapies.
In part 1 of this Review, we cover the following topics: diagnosis, neuromuscular 
management, rehabilitation management, endocrine management (including growth, 
puberty, and adrenal insufficiency), and gastrointestinal management (including nutrition 
and dysphagia). Parts 2 and 3 of this Review describe the care considerations for other topic 
areas, including an expanded section on psychosocial management and new sections on 
primary care, emergency management, and transitions of care across the lifespan. Figure 1 
provides an overview of assessments and interventions across all topics, organised by stage 
of disease.
Methods
In 2014, based on their clinical perspectives and expertise, the DMD Care Considerations 
Working Group (CCWG) steering committee identified 11 topics to be included in this 
update of the 2010 DMD care considerations.6 Eight of the topics were addressed in the 
original care considerations: (1) diagnosis, (2) neuromuscular management, (3) 
rehabilitation management, (4) gastrointestinal and nutritional management, (5) respiratory 
management, (6) cardiac management, (7) orthopaedic and surgical management, and (8) 
psychosocial management. Three topics are new: (9) primary care and emergency 
management, (10) endocrine management (including growth, puberty, adrenal insufficiency, 
and bone health), and (11) transitions of care across the lifespan.
The guidance in this update is not conventionally evidence based. As is typical for a rare 
disease, few large-scale randomised controlled trials (RCTs) have been completed for DMD, 
with the exception of studies of corticosteroids.16 Therefore, as for the 2010 DMD care 
considerations,6,7 guidance was developed using a method that queries a group of experts on 
the appropriateness and necessity of specific assessments and interventions, using clinical 
scenarios.17 This method is intended to objectify expert opinion, and to make the guidance a 
true reflection of the views and practices of an expert panel, based on their interpretation and 
Birnkrant et al. Page 3
Lancet Neurol. Author manuscript; available in PMC 2018 March 27.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
application of the existing scientific literature. Using this approach, we were able to produce 
an essential toolkit for DMD care; only assessments and interventions that have been 
deemed both appropriate and necessary are recommended.
A comprehensive literature review was done to identify articles relevant to DMD care for 
each topic area, with the addition of key words for the new topics. A full description of the 
literature review strategy, table of search terms, and summaries of relevant literature are 
available in the appendix. From the search results, the steering committee selected articles 
containing information that might require the 2010 care considerations to be updated. 
Clinical scenarios were then developed on the basis of the content of those articles. For each 
of the 11 topic areas, a committee of experts was assembled. Using the RAND Corporation–
University of California Los Angeles Appropriateness Method (RAM),6,17 the committees 
established which assessments and interventions were both appropriate and necessary for the 
various clinical scenarios. For the RAM process, the committees had two rounds to establish 
appropriateness followed by one or two rounds on necessity. For the following sections, not 
all steps of the two-stage RAM rating process were required, either because of a lack of new 
literature since the 2010 care considerations were developed, or because immediate 
unanimous agreement was reached among committee members on the appropriateness and 
necessity of interventions: diagnosis, neuromuscular management, respiratory management, 
cardiac management, orthopaedic and surgical management, and psychosocial management. 
Additionally, the RAM method was not deemed to be applicable for two of the new sections: 
primary care and emergency management, and transitions of care across the lifespan. The 
committees for these sections reached consensus during their discussions without first rating 
clinical scenarios.
Diagnosis
Achieving a timely and accurate diagnosis of DMD is a crucial aspect of care. The method 
for diagnosing DMD has not changed significantly since 2010 (figure 2).6 The diagnostic 
process typically begins in early childhood after suggestive signs and symptoms are noticed, 
such as weakness, clumsiness, a Gowers’ sign, difficulty with stair climbing, or toe walking. 
Prompt referral to a neuromuscular specialist, with input from a geneticist or genetic 
counsellor, can avoid diagnostic delay.18 Less commonly, the diagnosis is considered as a 
result of developmental delay19 or increased concentrations of serum enzymes such as 
alanine aminotransferase, aspartate aminotransferase, lactate dehydrogenase, or creatine 
kinase. Occasionally, an increased alanine aminotransferase, aspartate aminotransferase, or 
lactate dehydrogenase concentration prompts an inappropriate focus on hepatic dysfunction, 
delaying the diagnosis of DMD.
Because approximately 70% of individuals with DMD have a single-exon or multi-exon 
deletion or duplication in the dystrophin gene, dystrophin gene deletion and duplication 
testing is usually the first confirmatory test. Testing is best done by multiplex ligation-
dependent probe amplification (MLPA)20 or comparative genomic hybridisation array,21 
since use of multiplex PCR can only identify deletions. Identification of the boundaries of a 
deletion or duplication mutation by MLPA or comparative genomic hybridisation array 
might indicate whether the mutation is predicted to preserve or disrupt the reading frame. If 
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deletion or duplication testing is negative, genetic sequencing should be done to screen for 
the remaining types of mutations that are attributed to DMD (approximately 25–30%).22 
These mutations include point mutations (nonsense or missense), small deletions, and small 
duplications or insertions, which can be identified using next-generation sequencing.23–25 
Finally, if genetic testing does not confirm a clinical diagnosis of DMD, then a muscle 
biopsy sample should be tested for the presence of dystrophin protein by 
immunohistochemistry of tissue cryosections or by western blot of a muscle protein extract.
Female carriers
Family members of an individual with DMD should receive genetic counselling to establish 
who is at risk of being a carrier. Carrier testing is recommended for female relatives of a boy 
or man who has been genetically confirmed to have DMD. If the relative is a child, then the 
American Medical Association ethical guidelines for genetic testing of children should be 
followed.26 Once identified, female carriers have several reproductive choices to consider, 
including preimplantation genetic diagnosis or prenatal genetic testing through chorionic 
villus or amniotic fluid sampling. Female carriers also need medical assessment and follow-
up, as described in the section on cardiac management in part 2 of this Review.
Newborn screening
The feasibility of newborn screening for DMD was first shown in the mid-1970s27 through 
measurement of creatine kinase concentrations from dried blood spots. Recently, a two-tier 
newborn screening diagnostic system was reported,2 in which samples that revealed an 
increased creatine kinase concentration were then tested for dystrophin gene mutations. 
Newborn screening studies for DMD have been done in several countries, but most have 
been discontinued,2,28 and DMD is not currently included on the Recommended Uniform 
Screening Panel,29 which is largely restricted to neonatal-onset disorders for which early 
treatment shows improved outcome. However, renewed interest in newborn screening has 
been building as a result of support among stakeholders and because emerging DMD 
therapies might prove to be most effective if they are initiated before symptom onset.30,31
Neuromuscular management
After diagnosis, the neuromuscular specialist will serve as the lead clinician, taking overall 
responsibility for care of the person with DMD and performing multiple roles and 
responsibilities across the individual’s lifetime (panel 1). The neuromuscular specialist is 
uniquely qualified to guide patients and their families through the increasingly complex and 
technological diagnostic and therapeutic landscape of contemporary DMD care.
Assessments
Consistent and reproducible clinical assessments of neuromuscular function done by trained 
practitioners underpin the management of DMD. Assessments described in the 2010 care 
considerations remain valid, and clinics should use a set of tests with which they are 
comfortable and for which they understand the clinical correlates. Multidisciplinary team 
members must work together to optimise consistency and avoid unnecessary test 
duplication. Suggested assessments are shown in the appendix and are discussed in the 
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section on rehabilitation management. Newer studies have shown the value of minimum 
clinically important differences, predictive capabilities of standardised functional 
assessments, and ranges of optimum responsiveness, confirming the importance of 
standardised functional assessments across a patient’s lifespan.32–35 Additionally, new 
assessment tools are helping to guide the management of older, non-ambulatory individuals, 
illustrating the importance of clinical testing throughout life.
Interventions
Physiotherapy, as described in the section on rehabilitation management, and treatment with 
glucocorticoids remain the mainstays of DMD treatment and should continue after loss of 
ambulation. Figure 3 describes glucocorticoid initiation and use.36 The benefits of long-term 
gluco corticoid therapy have been shown to include loss of ambulation at a later age, 
preserved upper limb and respiratory function, and avoidance of scoliosis surgery.37 Recent 
studies confirm the benefits of starting glucocorticoids in younger children, before 
significant physical decline;38,39 an ongoing trial (ClinicalTrials.gov identifier 
NCT02167217) of weekend dosing in boys younger than 30 months will soon yield 
additional insights. Although the benefits of glucocorticoid therapy are well established, 
uncertainty remains about which glucocorticoids are best and at what doses.40 These 
uncertainties increase the risk of undertreatment or overtreatment, which could confound the 
results of trials of innovative therapies. Large-scale natural history and cohort studies 
confirm prolongation of ambulation from a mean of 10.0 years in individuals treated with 
less than 1 year of corticosteroids to a mean of 11.2 years in individuals treated with daily 
prednisone and 13.9 years in individuals taking daily deflazacort.41 In a few studies, 
weekend-only dosing of prednisone has shown efficacy equal to that of daily dosing.41,42 A 
phase 3 double-blind RCT compared deflazacort 0.9 mg/kg per day, deflazacort 1.2 mg/kg 
per day, prednisone 0.75 mg/kg per day, and placebo. All treatment groups had improved 
muscle strength compared with placebo and deflazacort was associated with less weight gain 
than prednisone.14 The benefit-to-risk ratio of deflazacort compared with prednisone is 
being studied further in an ongoing double-blind trial.15
Emerging treatments
The drug development pipeline for DMD has changed dramatically since the publication of 
the 2010 care considerations, and the full list of DMD treatment trials changes continually; 
updated information is available at ClinicalTrials.gov and the WHO International Clinical 
Trials Registry Platform. DMD is a rare disease, and the increasing number of DMD trials is 
a challenge for clinical trial capacity because of the low numbers of patients who qualify for 
participation. The need to optimise patient recruitment is expected to promote initiatives 
supporting trial readiness, such as patient registries, identification of clinically significant 
outcome measures, and natural history studies.
In August, 2014, ataluren was granted conditional marketing authorisation by the European 
Commission for use in the European Union, targeting the approximately 11% of boys with 
DMD caused by a stop codon in the dystrophin gene.43,44 In September, 2016, the US Food 
and Drug Administration (FDA) approved use of eteplirsen, which targets the approximately 
13% of boys with a mutation in the dystrophin gene that is amenable to exon 51 skipping,45 
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via an accelerated approval pathway. Ataluren and eteplirsen are the first of a series of 
mutation-specific therapies to gain regulatory approval. Other dystrophin restoration 
therapies are in development and some are near or in regulatory review.13 The FDA has also 
granted full approval for deflazacort, making this the first glucocorticoid with a labelled 
indication specifically for DMD.
Other drug classes in trials for DMD include drugs targeting myostatin, anti-inflammatory 
and antioxidant molecules, compounds to reduce fibrosis, drugs to improve vasodilatation, 
drugs to improve mitochondrial function, and drugs to regulate utrophin.46 However, 
without completed clinical studies and regulatory approval, none of these drugs can be 
prescribed for individuals with DMD.
Rehabilitation management
DMD is characterised by well known patterns of progressive muscle degeneration and 
weakness, postural compensations, risk of progressive contracture and deformity, and 
functional losses resulting from dystrophin deficiency.6,7 Improved DMD management has 
resulted in prolongation of ambulation,47 decreased prevalence of severe contracture and 
deformity, including scoliosis,37 and prolonged function and participation in all areas of life.
47,48
 Rehabilitation personnel include physicians, physical therapists, occupational 
therapists, speech-language pathologists, orthotists, and durable medical equipment 
providers. Panel 2 and the appendix present an overview of suggested assessments and 
interventions. Rehabilitation management requires an understanding of DMD pathology, 
pathokinesiology, natural history, and disease progression; providers should consider each 
individual’s goals and lifestyle to optimise quality of life across the lifespan.7 Assessment 
and anticipatory management must be provided across all domains of the International 
Classification of Functioning, Disability and Health (ICF), from diagnosis onwards, to 
minimise contractures, deformity, loss of function, compromised skin integrity, pain, and 
compromised cardiorespiratory status.
Assessments
Multidisciplinary rehabilitation assessment includes measures of passive ranges of motion, 
muscle extensibility, posture and alignment, strength, function, quality of life, and 
participation in all normal activities of everyday life (panel 2; appendix).7,32–35,49–59 
Specialised functional assessment includes analysis of patterns of movement and 
standardised assessments specific to DMD and other neuromuscular disorders.32,33,60 The 
North Star Ambulatory Assessment (NSAA) and timed function tests are foundational 
clinical assessments of function during the ambulatory period and should be done every 6 
months.32–35,50,54–56,61 The NSAA and timed function tests have high validity and 
reliability, as well as correlation between tests across time, minimum clinically important 
differences, and predictive capabilities regarding functional motor changes that are 
important in monitoring clinical progression and assessing new and emerging therapies.
32–35,55,56,62
 Identification of optimally responsive test ranges improves predictive 
capabilities, as in the 6-min walk test, in which understanding of interactions between age, 
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baseline distance, and genetics might allow improved research design and inform clinical 
care.35,63–66
Prediction of functional change in clinical settings should be made in the context of a 
patient’s capabilities, with awareness of limitations in effort-based assessments, potential 
interactions with musculoskeletal impairments such as contracture, and genetics.66,67 Tests 
that predict potential upcoming changes can be used to guide proactive care, such as 
impairment-level interventions and future equipment needs. Specifically, before age 7 years, 
gains might occur in the 6-min walk test and timed function tests. After 7 years, a 6-min 
walk test result of less than 325 m, time to stand more than 30 sec, time to climb four stairs 
more than 8 s, 10-min walk or run time more than 10–12 s, and mean linearised NSAA 34 or 
less (raw score of nine) have been associated with greater functional decline in ambulation 
over the subsequent 12 months.35,68 Functional assessment includes the assessment of 
activities of daily living and the need for adaptive equipment or assistive technology. 
Additionally, various tools can be used to assess quality of life.69–72
Increasing use of standardised testing in infants and young children with DMD is timely 
because of new potential for early diagnosis with newborn screening and the emergence of 
therapies that might work best if used in early childhood (appendix). The Bayley-III scale of 
infant development and Griffiths Mental Development Scales measure the rate of 
development in children, and both have the ability to highlight early developmental delays in 
children with DMD.49,50,73 The NSAA, with revision, can be used to test children as young 
as 3 years.51,74 Hip kinematics during gait are clinically meaningful outcome measures at 4–
8 years.75 Other measures assessing antigravity function, considered exploratory in DMD, 
include the Alberta Infant Motor Scale, Hammersmith Functional Motor Scale Expanded, 
and the Gross Motor Function Measure.49,61,76 Assessment of, and intervention for, 
learning, attention, and sensory processing should begin at young ages.77,78 In older 
individuals who are non-ambulatory, the Brooke Upper Extremity Scale, Egen Klassifikation 
scale, and elbow flexion and grip strength are responsive to change over 1–2 years,57,79,80 
with testing now including reachable workspace52,81 and assessment of upper limb function 
(performance of upper limb test).51,53,58
Consistent use of the same functional measures by individual clinics is recommended for 
tracking change over time, with inclusion of new assessments as appropriate. Assessment by 
rehabilitation specialists is recommended at least every 4–6 months throughout life, with 
more frequent assessment triggered by a clinical concern, a change in status, or specific 
needs.
Interventions
Direct physical, occupational, and speech and language therapy should be provided in 
outpatient and school settings and continue throughout adulthood, augmented by therapies 
provided during hospital admissions and at home (panel 2; appendix).
The goal of muscle extensibility and joint mobility management is to prevent or minimise 
contracture and deformity (panel 2). The inability to move a joint through its full range of 
motion, chronic static positioning, muscle imbalance about a joint, and fibrotic changes in 
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muscles cause decreased muscle extensibility and joint contractures.7 Restricted patterns of 
breathing and fibrosis of intercostal muscles decrease chest wall mobility. The maintenance 
of passive ranges of movement, muscle extensibility, chest wall mobility, and symmetry can 
optimise movement and functional positioning, maintain ambulation, prevent fixed 
contractures and deformities, optimise respiratory function, and maintain skin integrity.7 
Musculoskeletal management requires a team approach, with input from neuromuscular 
specialists, physical therapists, occupational therapists, rehabilitation physicians, orthotists, 
and orthopaedic surgeons.
Prevention of contracture and deformity requires daily passive stretching of joints, muscles, 
and soft tissues at risk of tightness; support of movement by decreasing the effects of gravity 
and optimising biomechanics to allow more active movement; manual therapy techniques 
and prolonged elongation of soft tissues; and optimal positioning, including individualised 
use of splinting, orthotic interventions, standing devices, serial casting, and custom seating 
and power positioning components in mobility devices.7,82 A daily preventive home 
stretching programme83 should begin before the loss of passive ranges of motion under the 
guidance of physical and occupational therapists. Stretching is recommended for areas 
known to be at risk of contracture or deformity (panel 2). Regular stretching of ankle, knee, 
and hip should begin soon after diagnosis and continue into adulthood. Stretching of the 
upper extremities is especially important after loss of ambulation.7
The appendix provides an overview of care considerations regarding various assistive and 
mobility devices, including ankle-foot orthoses, knee-ankle-foot orthoses, serial casting, 
standing devices, and manual and motorised mobility devices.7 Power stand-and-drive 
motorised wheelchairs are now frequently used in place of knee-ankle-foot orthoses to 
support standing mobility. Such orthoses might still be an appropriate choice in some 
situations, but should be viewed as therapeutic rather than functional tools, supplementing 
rather than replacing motorised mobility.84,85 Additionally, technological innovations—from 
simple devices (eg, elevated lap trays and adaptive straws) to more advanced technologies 
(eg, robotics, bluetooth capabilities that permit remote activation of devices, infrared 
environmental controls, smart phones, tablets, computers, and advanced access capabilities 
such as voice activation in the home)—can optimise function. Possible adaptive equipment 
and home renovations include patient hoists (lifts) for safe transfers, ramps, stair lifts, 
bathing and bathroom equipment or renovations, special beds and mattresses, and vehicle 
modifications. Personal care attendants can help to optimise independence and participation.
Physical therapists prescribe, monitor, and guide exercise, which can prevent an 
unnecessarily sedentary or immobile lifestyle and the associated problems of social isolation 
and overweight. However, the effects of exercise on muscle degeneration in 
dystrophinopathies, although not fully understood, can include damage due to structural 
fragility of muscles, metabolic abnormalities, nitric oxide abnormalities contributing to 
ischaemia during exercise, and reduced exercise capacity.7,86–89 Eccentric muscle activity or 
exercise and high-resistance exercise or strength training should be avoided.7,90 Submaximal 
aerobic exercise or activity has been recommended, especially early in the course of the 
disease—avoiding overexertion and overwork, and allowing adequate rest.7 Swimming is 
highly recommended from the early ambulatory stage and can be frequently continued into 
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adulthood.7 Cycling has been recommended as a submaximal aerobic form of activity,91,92 
and assisted cycling and robotic-assisted movement can be used into adulthood. Safe 
physical activity can be supported by appropriate adaptive equipment and assistive 
technology.
Pain must be assessed and addressed in individuals at all ages.7,59,93 Interventions require 
comprehensive team management, including physical therapy, postural correction, orthotic 
intervention and splinting, wheelchair and bed enhancements that allow independent weight 
shift, position change and pressure relief, and pharmacological approaches. Back pain, 
particularly in the context of glucocorticoid treatment, should prompt assessment for 
vertebral fractures.7 A detailed discussion of fracture prevention and management is 
presented in part 2 of this Review.
Endocrine management
The endocrine complications of DMD and its treatment include impaired growth, delayed 
puberty, and adrenal insufficiency. The goals of endocrine care are to monitor growth and 
development, identify and diagnose hormone deficiencies, provide endocrine hormone 
replacement therapy when indicated, and prevent a life-threatening adrenal crisis. A few 
relevant expert-opinion papers and reviews have been published,94–96 but data are scarce on 
the safety and efficacy of growth hormone and testosterone therapy in individuals with 
DMD. The care considerations that follow are based on evidence and experience derived 
from use of these therapies in other diseases, with modifications for use in DMD (figure 4).
Growth
Impaired linear growth is common in individuals with DMD and exacerbated by 
glucocorticoid treatment.39,97 Linear growth should be assessed every 6 months until 
completion of puberty and attainment of final height. Standing height is the most appropriate 
measure in ambulatory individuals. Height should be plotted and followed on a standardised 
growth curve. Additionally, regular assessment of growth using a non-standing height 
measure should begin during the ambulatory stage to allow more accurate assessment after 
individuals lose ambulation. Arm span, ulnar length, tibia length, knee height, and 
segmentally measured recumbent length have all been used to assess growth in non-
ambulatory children;98 however, none has been validated in the DMD population, and all 
require specialised training or specialised equipment. We suggest that each institution select 
and use the measure that works best in its particular clinical environment.
A decline in growth trajectory, as evidenced by downward crossing of height percentile or an 
annualised height velocity of less than 4 cm per year, is consistent with impaired linear 
growth and indicates the need for referral to an endocrinologist. Individuals with a height of 
less than the third percentile should be referred, irrespective of growth trajectory. 
Assessment of impaired linear growth should include standard screening tests to assess for 
endocrine hormone or other abnormalities associated with growth failure. Few data show the 
safety and efficacy of recombinant human growth hormone in the DMD population. One 
retrospective study found a short-term benefit on height velocity; however, some boys with 
DMD had side-effects such as intracranial hypertension, glucose intolerance, and 
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progression of scoliosis.99 None of the published studies on recombinant human growth 
hormone has followed patients to their final height, and no studies have been large enough to 
establish reliably whether recombinant human growth hormone therapy has a negative effect 
on muscle function or other adverse effects. Additionally, theoretical concerns have been 
raised that tall stature might be detrimental to muscle function in DMD.100,101 Until more 
evidence is available, the routine use of recombinant human growth hormone to treat DMD-
related growth failure is not recommended. Instead, the decision to treat with recombinant 
human growth hormone should be based on a thorough discussion of the potential risks and 
benefits of the therapy, and preferably reserved for individuals with abnormal growth 
hormone stimulation test results.
Puberty
Delayed puberty due to hypogonadism is a potential complication of glucocorticoid therapy 
and can be psychologically distressing, impairing quality of life. The absence of pubertal 
development by age 14 years requires prompt referral to an endocrinologist. Biochemical 
testing using appropriate paediatric or ultrasensitive assays should be done to confirm the 
diagnosis of hypogonadism in individuals with evidence of delayed puberty. A radiograph of 
the left hand to establish bone age should also be considered.
Testosterone replacement therapy is recommended to treat confirmed hypogonadism in 
patients older than 14 years and can be considered in boys older than 12 years on 
glucocorticoids with absent pubertal development. Although no clinical trials have 
specifically assessed the use of testosterone in boys with DMD, it is considered the standard 
of care to treat pathological pubertal delay in the paediatric population and is recommended 
for the treatment of glucocorticoid-induced hypogonadism in adult men.102 The potential 
benefits of testosterone on emotional and physical health usually outweigh the potential 
side-effects, such as behavioural changes, acne, body odour, rapid growth spurt, and 
epiphyseal closure. A recent retrospective review found that testosterone was generally well 
tolerated and perceived to be beneficial by individuals with DMD and their families.103
In an attempt to mimic normal pubertal development, testosterone replacement should be 
initiated at a low dose and slowly increased to adult replacement doses over several years. 
Intramuscular or topical preparations can be used. Testosterone concentrations should be 
monitored closely in all individuals. Consideration should be given to assessment of lipids, 
haemoglobin, haematocrit, and blood glucose in treated individuals. A negative effect on an 
individual’s functional status or cardiac function should prompt the clinician to consider 
discontinuing testosterone therapy or reducing the dose.
Adrenal insufficiency
Adrenal insufficiency due to suppression of the hypothalamic-pituitary-adrenal (HPA) axis is 
a rare but life-threatening condition that can develop if glucocorticoids are stopped suddenly 
because of illness or discontinuation of therapy.104 All individuals prescribed 
glucocorticoids should be educated about the signs, symptoms, and management of adrenal 
crisis and receive prescriptions for intramuscular hydrocortisone for emergency 
administration at home (50 mg for children <2 years; 100 mg for children or adults ≥2 
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years). Stress dosing with hydrocortisone at 50–100 mg/m2 per day might also be required in 
the setting of severe illness, major trauma, or surgery in individuals taking more than 12 
mg/m2 per day of prednisone or deflazacort. Glucocorticoid therapy should not be 
discontinued abruptly but rather tapered over weeks to months to allow HPA axis recovery.
105
 The PJ Nicholoff Steroid Protocol is an appropriate approach to glucocorticoid (steroid) 
tapering (figure 3).36
Gastrointestinal and nutritional management
Individuals with DMD often have gastrointestinal or nutritional complications, including 
weight gain or loss, dietary or nutrient imbalance, fluid imbalance, low bone density, 
swallowing dysfunction, and mandibular contracture.106 Contributing factors include 
glucocorticoid treatment, decreased energy expenditure, and immobility.107 These 
nutritional imbalances can negatively affect the respiratory, skeletal muscle, and cardiac 
systems.
The aim of nutritional care is to prevent overweight or obesity and undernutrition or 
malnutrition through regular assessment of growth and weight; it also aims to promote a 
healthy, balanced diet, with optimum intake of calories, protein, fluid, and micronutrients, 
especially calcium and vitamin D. Robust evidence-based nutrition research specific to 
DMD is lacking. Nutrition recommendations applicable to DMD are therefore adapted from 
those for the general population. The care team should include a registered dietitian 
nutritionist with appropriate experience, who should see an individual with DMD at every 
visit, beginning at diagnosis. More frequent monitoring by the dietitian nutritionist will be 
necessary during periods when weight gain or loss is anticipated. A physical therapist should 
be consulted to design and enact safe exercise programmes for individuals who are at risk of 
becoming overweight. A speech-language pathologist should be consulted to assess 
individuals for suspected dysphagia. A gastroenterologist should be consulted for 
management of constipation, gastroesophageal reflux, and gastrointestinal motility concerns, 
and when gastrostomy tube placement is needed. Figure 5 presents an overview of the 
recommended gastrointestinal and nutritional assessments and interventions.
Nutritional assessment and planning
At each clinic visit, the registered dietitian nutritionist should assess nutritional status, track 
weight and height, and create a specific nutritional plan. Good nutritional status is defined as 
weight for length, or body-mass index (BMI) for age, that falls between the tenth and 85th 
percentiles on standard growth charts. If BMI cannot be calculated because height cannot be 
measured, weight-for-age percentiles should be used. Individuals with DMD have altered 
body composition, so the use of standard growth charts is not optimal.
Patients and their family members should practice healthy, balanced eating as recommended 
in the current Dietary Guidelines for Americans.108 Adequate fluid intake should be 
emphasised, to prevent dehydration, which increases the risk of constipation and renal 
dysfunction.109 Panel 3 offers a general nutritional plan for people with DMD.110
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Monitoring of bone health requires annual assessments of dietary calcium intake and serum 
25-hydroxy-vitamin D concentration. If calcium intake is less than the recommended intake 
for age, or if serum 25-hydroxy-vitamin D decreases to less than 30 ng/mL, appropriate 
dietary intake and nutrient supplementation should be provided according to Institute of 
Medicine guidelines.114 For more details, see the section on bone health and osteoporosis 
management in part 2 of this Review.
DMD-specific nutritional risks
Individuals with DMD are at risk of overweight or obesity early in life, with an increased 
risk of undernutrition or malnutrition as they approach adulthood (appendix).115,116 In early 
childhood, glucocorticoid therapy increases the risk of overweight or obesity because of 
increased appetite and caloric intake, and sodium and fluid retention. Loss of ambulation 
leads to decreased activity, which reduces caloric needs and increases the risk of overweight 
or obesity. To address these risks, the clinician should create a nutritional plan that includes 
specific recommendations for calorie, protein, micronutrient, and fluid intake (panel 3). 
Caloric needs are estimated by calculating resting energy expenditure and adjusting for 
activity level (panel 3). Healthy eating habits, as suggested by the American Academy of 
Pediatrics Committee on Nutrition guidelines for the prevention of obesity, should be 
followed by the entire family (appendix).117 If weight gain is excessive, an obesity 
management plan should be created that addresses both diet and physical activity.
Swallowing dysfunction (dysphagia) is common and frequently progressive in patients with 
DMD. Anticipatory assessment for dysphagia is important and should be done regularly.118 
Screening questions should focus on perceived difficulty with swallowing of liquids and 
solids, perception of food sticking in the throat, time necessary to eat an average meal, and 
interference of eating with quality of life.119 If a patient responds to screening questions in 
the affirmative, the speech-language pathologist should be consulted for a comprehensive 
assessment, including a video fluoroscopic swallowing study.120
Individuals often lose weight unintentionally before and during the onset of clinical 
symptoms of dysphagia. Their BMI or weight percentiles might decrease from the 
overweight or obese category into the normal range or into the underweight (malnutrition) 
range as a result of feeding difficulties and disease progression. Care considerations for 
reducing the risk of underweight or malnutrition during this transition period are provided in 
the appendix.
Early and ongoing discussion of gastrostomy tube feeding can facilitate timely intervention 
when clinically indicated. The family and care team should consider gastrostomy tube 
placement to be a necessary and positive intervention when progressive weakness interferes 
with self-feeding and swallowing. Indications for gastrostomy tube placement include 
malnutrition that is unresponsive to interventions to improve oral caloric intake, diagnosis of 
moderate or severe dysphagia, and inability to maintain adequate hydration. Gastrostomy 
tube feeding leads to stabilisation or improvement of nutritional status in undernourished 
individuals with DMD.121 Assessment of the benefits of gastrostomy tube feeding should be 
discussed in the context of respiratory, cardiac, and anaesthetic risks of the procedure.
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Common gastrointestinal problems
Constipation is a very frequent complication of DMD.122 Risk factors include decreased 
colonic transit time, immobility, abdominal muscle weakness, and dehydration (panel 3). 
Daily treatment with osmotic laxatives such as polyethylene glycol, milk of magnesia, or 
lactulose might be necessary. Retrograde enemas might be helpful if faecal impaction 
occurs.
In DMD, risk factors for gastro-oesophageal reflux include oesophageal dysmotility, delayed 
gastric emptying time, glucocorticoid therapy, and scoliosis.123 Treatment of 
gastroesophageal reflux consists of gastric acid suppression using histamine-2 receptor 
antagonists such as ranitidine, or proton-pump inhibitors such as lansoprazole or 
omeprazole. The benefits of proton-pump inhibitors must be balanced against potential risks, 
including a higher incidence of community-acquired pneumonia, chronic kidney disease, 
and bone fracture.124,125 Dietary approaches include eating smaller, more frequent meals 
and decreasing dietary fat intake.
As skeletal muscle weakness progresses in individuals with DMD, a delay in gastric 
emptying (gastroparesis) can occur,123 which can lead to postprandial abdominal pain, 
nausea, vomiting, early satiety, and loss of appetite. Gastric emptying time can be assessed 
using a scintigraphic gastric emptying scan. Treatment options include dietary modification, 
pharmacological therapy, and postpyloric feeding via a gastrojejunal feeding tube.
Conclusions and future directions
In part 1 of this three-part update of the DMD care considerations, we have presented 
guidance on diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal 
management. Highlights of the new care considerations include guidance on the care of 
female carriers of DMD; an overview of new molecular and genetic therapies; advances in 
rehabilitation assessments and the emergence of more advanced, technologically enabled 
rehabilitation therapies; new guidance on endocrine problems, including growth, puberty, 
and adrenal insufficiency; and new insights into the anticipation and management of DMD-
specific nutritional complications, such as obesity in association with glucocorticoid therapy 
or loss of ambulation, and malnutrition in the advanced stages of DMD.
The possibility of newborn screening and the anticipated emergence of genetic and 
molecular disease-modifying treatments for DMD mean that earlier initiation of treatment 
will become increasingly important in the future. However, the optimum timing for initiation 
of new therapies will be a key factor in decisions to implement newborn screening for DMD. 
Non-invasive prenatal testing for DMD is likely to become clinically available, allowing 
earlier identification of affected fetuses in women without a family history of DMD.126
New dystrophin restorative therapies are becoming available, with more expected to follow, 
and more data are emerging on the best glucocorticoid regimens for patients with DMD.15 
Future care considerations will need to address the role of the new compounds in the overall 
management of DMD, especially in the context of the proven benefit of long-term 
glucocorticoid therapy. When some of these new therapies have been proven safe and 
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effective, treatment for DMD can be personalised, with selection of the best combination of 
therapies for each individual’s particular mutation. In terms of endocrine management, 
RCTs are needed to better understand the risks and benefits of growth hormone and 
testosterone therapy and to clarify the best indications, timing, and dosing regimens.
Improved clinical and functional assessments for rehabilitation management continue to be 
developed, with expansion across the lifespan. With advances in technology, new therapies 
will probably be assessed increasingly through activity monitoring in combination with 
measurements of new, clinically meaningful biomarkers.127 Robotics and other rapid 
advances in technology will improve independence, participation, and quality of life. 
Emerging therapies such as dystrophin-restorative therapies might improve exercise or 
activity capacity and safety. Interventions provided by physical therapists, occupational 
therapists, speech-language pathologists, and orthotists, alongside new technologies, will 
optimise musculoskeletal management and function.128
Finally, for gastrointestinal and nutritional management, research is needed on resting 
energy expenditure (measured by indirect calorimetry) and total energy expenditure 
(measured by the doubly labelled water method) to assess energy expenditure or kilocalorie 
needs for individuals with DMD. Specific nutritional strategies, such as the potential utility 
of a protein-enriched or fructose-enriched diet, or branched-chain aminoacid 
supplementation,129 and the influence of nutritional status on DMD outcomes (life 
expectancy, function, and quality of life) need to be better understood. More research is 
needed to develop DMD-specific growth charts, as well as accurate techniques to establish 
body composition in patients with DMD. The unique determinants of obesity in boys with 
DMD should be used to guide more feasible obesity prevention and management strategies, 
including pharmacological options. The development of safe and effective physical activity 
prescriptions could positively affect nutritional status, mobility, and social engagement 
throughout the life of patients with DMD.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Panel 1: Roles and responsibilities of the neuromuscular specialist in the care of 
patients with Duchenne muscular dystrophy
• Assess and characterise each patient’s unique disease trajectory over time 
using validated assessment tools, aiming to establish a patient’s expected 
clinical course and to advise on prognosis and potential complications
• Use assessment information to select therapeutic interventions that define a 
customised treatment plan designed to meet the particular needs and goals of 
each patient and family, optimising outcomes and quality of life as defined by 
the individual patient and family
• Engage specific clinicians who can enact the designated assessments, 
interventions, and treatment plan, ideally in the context of a dedicated, 
multidisciplinary DMD clinic that is led, administered, and coordinated by the 
neuromuscular specialist; assist in the care of female carriers, including 
cardiac assessment
• Be the first-line medical advisor to patients and their families as they define 
and revise their individual care goals over time, helping them to personalise 
their risk-to-benefit analysis of therapeutic interventions, including:
– Technological interventions for respiratory and cardiac management
– Surgical and non-surgical interventions, such as spinal fusion, 
contracture management, and provision of aids and appliances
– Pharmacological interventions, such as glucocorticoid therapy, 
emerging therapies, and patient participation in clinical research 
trials of investigational drugs
• Be an advocate for high-quality DMD care at patients’ institutions and in their 
communities, addressing issues such as transition of care from paediatric to 
adult clinical providers and provision of hospital care that is designed to 
address patients’ unique medical, physical, and psychosocial needs
• Help patients and families navigate end-of-life care in a way that preserves 
comfort, dignity, and quality of life as defined by each individual patient and 
family
Panel 2: Rehabilitation assessments and interventions across all disease stages for 
patients with Duchenne muscular dystrophy
Assessment
Multidisciplinary rehabilitation assessment every 6 months or more frequently if 
concerns, change in status, or specific needs are present (appendix)
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Intervention
Direct treatment
Direct treatment implemented by physical therapists, occupational therapists, and speech-
language pathologists, tailored to individual needs, stage of disease, response to therapy, 
and tolerance, provided across the patient’s lifespan
Prevention of contracture and deformity
• Daily preventive home stretching 4–6 times per week; regular stretching at 
ankles, knees, and hips; stretching of wrists, hands, and neck later if indicated 
by assessment
• Stretching for structures known to be at risk of contracture and deformity* 
and those identified by assessment
• Orthotic intervention, splinting, casting, positioning, and equipment:
– AFOs for stretching at night—might be best tolerated if started 
preventatively at a young age
– AFOs for stretching or positioning during the day in non-ambulatory 
phases
– Wrist or hand splints for stretching of long and wrist finger flexors/
extensors—typically in non-ambulatory phases
– Serial casting—in ambulatory or non-ambulatory phases
– Passive/motorised supported standing devices—when standing in 
good alignment becomes difficult, if contractures are not too severe 
to prevent positioning or tolerance
– KAFOs with locked knee joints—an option for late ambulatory and 
non-ambulatory stages
– Custom seating in manual and motorised wheelchairs (solid seat, 
solid back, hip guides, lateral trunk supports, adductors, and head 
rest)
– Power positioning components on motorised wheelchairs (tilt, 
recline, elevating leg rests, standing support, and adjustable seat 
height)
Exercise and activity
Regular submaximal, aerobic activity or exercise (eg, swimming and cycling) with 
assistance as needed, avoidance of eccentric and high-resistance exercise, monitoring to 
avoid overexertion, respect for the need for rests and energy conservation, and caution 
regarding potentially reduced cardiorespiratory exercise capacity as well as risk of 
muscle damage even when functioning well clinically
Falls and fracture prevention and management
• Minimisation of fall risks in all environments
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• Physical therapist support of orthopaedics in rapid team management of long-
bone fractures and provision of associated rehabilitation to maintain 
ambulation and/or supported standing capabilities
Management of learning, attentional, and sensory processing differences
Management in collaboration with team, based on concern and assessment
Assistive technology and adaptive equipment
Planning and education with assessment, prescription, training, and advocacy for funding
Participation
Participation in all areas of life supported at all stages
Pain prevention and management
Pain prevention and comprehensive management, as needed, throughout life
AFOs=ankle-foot orthoses. KAFOs=knee-ankle-foot orthoses. *Areas typically at risk of 
contracture and deformity include hip flexors, iliotibial bands, hamstrings, plantar 
flexors, plantar fascia, elbow flexors, forearm pronators, long wrist and finger flexors and 
extensors, lumbricals, and cervical extensors; isolated joint contracture into hip and knee 
flexion and plantar flexion, varus at hindfoot and forefoot, elbow flexion, wrist flexion or 
extension, and finger joints; and deformity of the vertebral column and chest wall 
including scoliosis, excessive kyphosis or lordosis, and decreased chest wall mobility.
Panel 3: General nutritional plan
This general nutritional plan, which is created from recommendations for the general 
healthy population and is not specific to patients with DMD, provides methods to assess 
energy, protein, fluid, and micronutrient requirements on the basis of dietary reference 
intakes. To meet the body’s daily nutritional needs while minimising risk of chronic 
disease, adults should consume 45–65% of their total calories from carbohydrates, 20–
35% from fat, and 10–35% from protein. The acceptable ranges for children are similar 
to those for adults, except that infants and younger children need a somewhat higher 
proportion of fat in their diets.110
Overall caloric needs
Overall caloric needs are based on total energy expenditure, which is equal to resting 
energy expenditure (REE) multiplied by the physical activity factor.
Indirect calorimetry provides the most accurate measure of REE, but REE can also be 
estimated in steroid-treated ambulatory boys with DMD (aged 10–17 years) by the 
Schofield weight equation (REE [kilocalories] = [17.7 × weight in kg + 657] × 
4.182/1000).111 Because of the decline in physical activity that accompanies a loss of 
ambulation, calorie needs can decrease substantially, and REE might be even lower than 
the REE before the loss-of-ambulation phase.
Physical activity factors for boys aged 3–18 years are sedentary (1.00), low active (1.13), 
active (1.26), and very active (1.42).
Birnkrant et al. Page 28
Lancet Neurol. Author manuscript; available in PMC 2018 March 27.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
The calculated energy or caloric intake will need to be decreased if initial energy or 
caloric prescription does not result in weight maintenance or weight loss. If the goal is 
weight increase, the calculated energy or caloric intake will need to be increased.
Protein
Recommended dietary allowance for protein differs for boys and men according to age: a 
dietary allowance of 0.95 g/kg bodyweight per day is recommended for children aged 4–
13 years; 0.85 g/kg per day is recommended for those aged 14–18 years; and 0.80 g/kg 
per day is recommended for men aged 19 years or older.
Fluids
Recommended fluid intake (total beverages, including drinking water) is based on weight 
or age.
Based on weight, the Holliday–Segar maintenance fluid method112 recommends 100 
mL/kg bodyweight for children who weigh 1–10 kg; 1000 mL + 50 mL for each kg over 
10 kg for children who weigh 10–20 kg; and 1500 mL + 20 mL for each kg over 20 kg 
for children and adults who weigh more than 20 kg.
Based on age, the daily dietary reference intake values for fluids are 1.2 L (approximately 
5 cups) for boys and girls aged 4–8 years; 1.8 L (approximately 8 cups) for boys aged 9–
13 years; 2.6 L (approximately 11 cups) for boys aged 14–18 years; and 3.0 L 
(approximately 13 cups) for men aged 19 years or older.
Micronutrients
Recommended dietary allowance for age113 should be followed, except in the case of 
vitamin D deficiency, which is defined as 25-hydroxyvitamin D of less than 30.0 ng/mL. 
A multivitamin or mineral supplement is necessary if calorie intake is low.
Search strategy and selection criteria
We searched Medline, Embase, Web of Science, and the Cochrane Library databases for 
peer-reviewed English-language articles published from Jan 1, 2006, to Sept 30, 2013, for 
the eight original topics and from Jan 1, 1990, to Sept 30, 2013, for the three new topics. 
The literature was searched using the key search terms “Duchenne” or “muscular 
dystrophy,” or both, paired with one of 626 search terms (appendix). The literature search 
identified 1215 articles after duplicates were removed. Reviews, meta-analyses, case 
series, case reports, studies of animal models, and articles on unrelated diseases or 
Becker’s muscular dystrophy only were excluded upon further review. Of the 672 
remaining articles, the steering committee reviewed 430 articles that were potentially 
relevant to the update of the care considerations. The steering committee members then 
classified each one using the following criteria: (1) consistent with the existing care 
considerations; (2) conflicts with the existing care considerations; (3) requires an update 
to the care considerations; or (4) presents promising research. Articles that were 
identified as required for the update were used to create clinical scenarios in accordance 
with the RAND Corporation–University of California Los Angeles Appropriateness 
Method. Subject matter experts, with the assistance of RTI International, also continually 
updated the references during the development of the manuscript. Before publication, an 
Birnkrant et al. Page 29
Lancet Neurol. Author manuscript; available in PMC 2018 March 27.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
updated literature search was done for articles published between Oct 1, 2013, and July 
31, 2017, which identified 880 articles. Committee chairs reviewed 115 articles 
potentially relevant to care and updated the references and text as necessary.
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Figure 1. Comprehensive care of individuals with Duchenne muscular dystrophy
Care for patients with Duchenne muscular dystrophy is provided by a multidisciplinary team 
of health-care professionals; the neuromuscular specialist serves as the lead clinician. The 
figure includes assessments and interventions across all disease stages and topics covered in 
this three-part Review.
*Echocardiogram for patients 6 years or younger. †Cardiac MRI for patients older than 6 
years.
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Figure 2. Diagnosis of Duchenne muscular dystrophy
Described early signs and symptoms of DMD are based on Ciafaloni and colleagues.18 
DMD=Duchenne muscular dystrophy.
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Figure 3. Care considerations for glucocorticoid (steroid) initiation and use for patients with 
Duchenne muscular dystrophy
ACTH=adrenocorticotropic hormone. CRH=corticotropin-releasing hormone. 
HPA=hypothalamic-pituitary-adrenal.
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Figure 4. 
Assessments and interventions for impaired growth and delayed puberty in patients with 
Duchenne muscular dystrophy.
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Figure 5. 
Assessments and interventions for nutritional, swallowing, and gastrointestinal management 
in patients with Duchenne muscular dystrophy.
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